organization · Reporting owner
Puissance Capital Management LP
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ChronoScale Holdings CorpEKSO · Entity 4331 | 10% owner | July 23, 2020 | July 27, 2020 |
| ViewRay, Inc.VRAY · Entity 111118 | 10% owner | January 18, 2017 | January 25, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ChronoScale Holdings Corp
Report date July 23, 2020 · Filed July 27, 2020
Jointly reported with Wang Theodore T, Puissance Cross-Border Opportunities II LLC, Puissance Capital Fund (GP) LLC, Puissance Capital Management (GP) LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,958 |
Reported balance
After 2020-07-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-07-23 · Grant · Acquired 7,383 · Balance 9,958 F1: The grant consists of RSUs that fully vest one year from the date of grant, or July 23, 2021. F2: After taking into account the 1-for-15 reverse stock split effective March 24, 2020. |
| Common StockSEC Table I · non-derivative | IndirectBy Puissance Cross-Border Opportunities II LLC | 774,400 |
Reported balance
Holding disclosure · report date 2020-07-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 774,400 F2: After taking into account the 1-for-15 reverse stock split effective March 24, 2020. F3: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant consists of RSUs that fully vest one year from the date of grant, or July 23, 2021.
F2: After taking into account the 1-for-15 reverse stock split effective March 24, 2020.
F3: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
ViewRay, Inc.
Report date January 18, 2017 · Filed January 25, 2017
Jointly reported with Puissance Cross-Border Opportunities I LP, Puissance Capital Fund (GP) LLC, Puissance Capital Management (GP) LLC, Wang Theodore T
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,842,975 |
Reported balance
Holding disclosure · report date 2017-01-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,842,975 F1: These securities may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities I LP; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities I LP; and Theodore Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities I LP; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities I LP; and Theodore Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bellerophon Therapeutics, Inc.
Report date October 13, 2023 · Filed October 16, 2023
Jointly reported with Puissance Life Science Opportunities Fund VI, Puissance Capital Fund (GP) LLC, Wang Theodore T
Section 16 reporting ended · disclosed 2023-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-13 · Sale · Disposed 1,076,841 · Balance 0 |
Tracon Pharmaceuticals, Inc.
Report date December 05, 2019 · Filed December 11, 2019
Jointly reported with Puissance Cross-Border Opportunities V LLC, Puissance Cross-Border Opportunities IV LLC, Puissance Capital Fund (GP) LLC, Puissance Capital Management (GP) LLC, Wang Theodore T
Section 16 reporting ended · disclosed 2019-12-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy funds | 416,182 |
Reported balance
After 2019-12-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-12-05 · Sale · Disposed 43,996 · Balance 416,182 F1: Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 43,996 shares of common stock. F2: Consists of: 239,190 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Shares directly owned Puissance Cross-Border Opportunities IV LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy funds | 76,048 |
Reported balance
After 2019-12-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-12-09 · Sale · Disposed 340,134 · Balance 76,048 F3: Puissance Cross-Border Opportunities IV LLC made an in-kind distribution of 176,992 shares of common stock. Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 163,142 shares of common stock. F4: Consists of: 76,048 Shares directly owned by Puissance Cross-Border Opportunities V LLC. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2024-03-27 | IndirectBy funds | 460,178 |
Reported balance
Holding disclosure · report date 2019-12-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 460,178 F5: Consists of: 283,186 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Warrants directly owned Puissance Cross-Border Opportunities IV LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 43,996 shares of common stock.
F2: Consists of: 239,190 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Shares directly owned Puissance Cross-Border Opportunities IV LLC.
F3: Puissance Cross-Border Opportunities IV LLC made an in-kind distribution of 176,992 shares of common stock. Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 163,142 shares of common stock.
F4: Consists of: 76,048 Shares directly owned by Puissance Cross-Border Opportunities V LLC.
F5: Consists of: 283,186 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Warrants directly owned Puissance Cross-Border Opportunities IV LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2023 Filed Oct 16, 2023 20:51 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 1,076,841 | $0.10 | $111,776.10 |
DisclosureSEC source: 0001760460-23-000008 · primary_doc.xml · nonDerivative · entry 1 Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:21 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 134,421 | $0.83 | $111,569.43 |
DisclosureSEC source: 0001760460-23-000006 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,841 Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:55 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 560,000 | $9.46 | $5,297,600.00 |
DisclosureSEC source: 0001760460-23-000003 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,211,262 Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 12:37 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 8,189 | $4.00 | $32,756.00 |
DisclosureSEC source: 0001760460-21-000004 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,262 F1 · ownership.direct: 1. These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantWarrants (Right to buy) · Derivative | 304,286 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · derivative · entry 3 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,236 Underlying: Common Stock · 304,286 shares Expires 2022-09-29 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantWarrants (Right to buy) · Derivative | 380,950 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · derivative · entry 2 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,950 Underlying: Common Stock · 380,950 shares Expires 2023-11-29 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 609,231 | $4.00 | $2,436,924.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763,077 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 16:42 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantCommon Stock | 7,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043737 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,958 F1 · price: The grant consists of RSUs that fully vest one year from the date of grant, or July 23, 2021. F2 · balance_after: After taking into account the 1-for-15 reverse stock split effective March 24, 2020. Read SEC document |
| May 21, 2020 Filed May 22, 2020 07:25 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 1,153,846 | $13.00 | $14,999,998.00 |
DisclosureSEC source: 0001760460-20-000002 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,153,846 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 10:47 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | OtherCommon Stock | 553,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001718111-20-000001 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities III LLC · CIK 0001718111 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Puissance Cross-Border Opportunities III LLC Disclosed balance after: 0 F1 · kind: Puissance Cross-Border Opportunities III LLC made an in-kind distribution of an aggregate 553,250 shares of the Issuer's common stock to its limited partners in connection with the redemption of partnership interests. F1 · price: Puissance Cross-Border Opportunities III LLC made an in-kind distribution of an aggregate 553,250 shares of the Issuer's common stock to its limited partners in connection with the redemption of partnership interests. F2 · ownership.direct: These securities are held directly by Puissance Cross-Border Opportunities III LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities III LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities III LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 20:42 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | OtherCommon Stock | 8,918,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001717781-20-000001 · primary_doc.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Puissance Cross-Border Opportunities II LLC Disclosed balance after: 11,616,000 F1 · kind: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 8,918,898 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests. F1 · price: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 8,918,898 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests. F2 · ownership.direct: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:58 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantStock Option (right to buy) · Derivative | 136,496 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-20-004378 · doc4.xml · derivative · entry 3 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,496 Underlying: Common Stock · 136,496 shares Expires 2030-01-16 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of July 1, 2019. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:58 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantCommon Stock | 19,445 | $0.45 | $8,750.25 |
DisclosureSEC source: 0001209191-20-004378 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,624 Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 10:47 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 340,134 | $2.92 | $993,191.28 |
DisclosureSEC source: 0001733439-19-000001 · primary_doc.xml · nonDerivative · entry 2 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 76,048 F3 · shares: Puissance Cross-Border Opportunities IV LLC made an in-kind distribution of 176,992 shares of common stock. Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 163,142 shares of common stock. F4 · ownership.direct: Consists of: 76,048 Shares directly owned by Puissance Cross-Border Opportunities V LLC. Read SEC document |
| December 05, 2019 Filed Dec 11, 2019 10:47 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 43,996 | $3.05 | $134,187.80 |
DisclosureSEC source: 0001733439-19-000001 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 416,182 F1 · shares: Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 43,996 shares of common stock. F2 · ownership.direct: Consists of: 239,190 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Shares directly owned Puissance Cross-Border Opportunities IV LLC. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 10:14 UTC Amendment | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 4,326 | $1.21 | $5,234.46 |
DisclosureSEC source: 0001733439-18-000016 · primary_doc.xml · nonDerivative · entry 2 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,601,768 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 10:14 UTC Amendment | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,326 | $1.13 | $4,888.38 |
DisclosureSEC source: 0001733439-18-000016 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,606,094 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 09:39 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 4,326 | $1.21 | $5,234.46 |
DisclosureSEC source: 0001733439-18-000015 · primary_doc.xml · nonDerivative · entry 2 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,601,768 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 09:39 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,326 | $1.13 | $4,888.38 |
DisclosureSEC source: 0001733439-18-000015 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,606,094 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 21:05 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantEmployee Stock Option (right to buy) · Derivative | 41,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-18-045772 · doc4.xml · derivative · entry 3 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2028-08-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of June 7, 2018. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 21:05 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantCommon Stock | 19,179 | $1.79 | $34,330.41 |
DisclosureSEC source: 0001209191-18-045772 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,179 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.